SCHEMBL3688490

SCHEMBL3688490

O=C(O)c1nc2c(C(F)(F)F)cc(-c3ccccc3)cn2c1Br

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LDHA P00338 3/20 0.43
HDAC6 Q9UBN7 1/20 0.38
PTGER1 P34995 2/20 0.38
ALDH1A1 P00352 2/20 0.37
APOBEC3A P31941 1/20 0.37
CTDSP1 Q9GZU7 1/20 0.37
APOBEC3G Q9HC16 1/20 0.37
GAA P10253 1/20 0.37
POLB P06746 2/20 0.36
KMT2A Q03164 1/20 0.36
TAS2R14 Q9NYV8 2/20 0.35
DHODH Q02127 1/20 0.35
TRPA1 O75762 1/20 0.35
KDM4E B2RXH2 2/20 0.34
PIN1 Q13526 1/20 0.34
HSD17B10 Q99714 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
PTGFR P43088 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3688388 0.90 PIN1 (0.41) LDHAALDH1A1DHODHKDM4EPIN1
SCHEMBL3690057 0.86 LDHA (0.44) LDHAHDAC6PTGER1ALDH1A1GAA
SCHEMBL3689623 0.85 LDHA (0.43) LDHAHDAC6PTGER1ALDH1A1GAA
SCHEMBL1583475 0.85 ERN1 (0.40) LDHAPTGER1
SCHEMBL3703406 0.84 ALDH1A1 (0.45) LDHAALDH1A1GAAPOLBKMT2A
SCHEMBL3689267 0.83 PTGER1 (0.36) PTGER1TAS2R14PIN1
SCHEMBL3685886 0.82 MARK3 (0.35) PTGER1
SCHEMBL3687958 0.81 MDM2 (0.40) APOBEC3ACTDSP1APOBEC3G
SCHEMBL1583997 0.81 PTGER1 (0.33) PTGER1
SCHEMBL7490255 0.79 SMN1; SMN2 (0.45) ALDH1A1GAAPOLBKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections GLAXOSMITHKLINE LLC 2012-05-17 US disclosed
EP-2187883-A2 NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2010-05-26 EP disclosed
US-20090176778-A1 Certain nitrogen containing bicyclic chemical entities for treating viral infections GLAXOSMITHKLINE LLC 2009-07-09 US disclosed
WO-2009023179-A2 NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2009-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections OAT, HAVCR2, CPS1 LDHA 512/4885HDAC6 746/4885PTGER1 1091/4885
US-20090176778-A1 Certain nitrogen containing bicyclic chemical entities for treating viral infections OAT, HAVCR2, CPS1 LDHA 512/4885HDAC6 746/4885PTGER1 1091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.